MA42317B2 - Combination vaccine composition for multiple administration - Google Patents

Combination vaccine composition for multiple administration

Info

Publication number
MA42317B2
MA42317B2 MA42317A MA42317A MA42317B2 MA 42317 B2 MA42317 B2 MA 42317B2 MA 42317 A MA42317 A MA 42317A MA 42317 A MA42317 A MA 42317A MA 42317 B2 MA42317 B2 MA 42317B2
Authority
MA
Morocco
Prior art keywords
vaccine
combination vaccine
vaccine composition
multiple administration
immunogenic composition
Prior art date
Application number
MA42317A
Other languages
French (fr)
Inventor
Suk Young Choi
Yoon Ae Noh
Eun Ji Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA42317B2 publication Critical patent/MA42317B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A61K31/115—Formaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition immunogène à doses multiples pour un vaccin combiné multivalent, dans laquelle (i) le vaccin combiné multivalent contient un vaccin contre la coqueluche vaccin à cellules entières (wp) ou un vaccin contre la coqueluche acellulaire(ap), et un vaccin contre la polio inactivé sabin (sipv) ; et (ii) la composition contient du 2-phénoxyéthanol (2-pe) et du formaldéhyde (hcho) en tant que conservateurs ; et un procédé de préparation d'une composition immunogène à dThe present invention relates to a multiple dose immunogenic composition for a multivalent combination vaccine, wherein (i) the multivalent combination vaccine contains a pertussis vaccine whole cell vaccine (wp) or a vaccine against acellular pertussis (ap), and sabin inactivated polio vaccine (sipv); and (ii) the composition contains 2-phenoxyethanol (2-pe) and formaldehyde (hcho) as preservatives; and a method of preparing an immunogenic composition with d

MA42317A 2015-09-16 2016-09-13 Combination vaccine composition for multiple administration MA42317B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150131157 2015-09-16
PCT/KR2016/010313 WO2017048038A1 (en) 2015-09-16 2016-09-13 Combination vaccine composition for multiple-dosage

Publications (1)

Publication Number Publication Date
MA42317B2 true MA42317B2 (en) 2021-11-30

Family

ID=58289554

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42317A MA42317B2 (en) 2015-09-16 2016-09-13 Combination vaccine composition for multiple administration
MA52400A MA52400B1 (en) 2015-09-16 2016-09-13 Combined vaccine composition for multiple administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA52400A MA52400B1 (en) 2015-09-16 2016-09-13 Combined vaccine composition for multiple administration

Country Status (7)

Country Link
KR (1) KR101864029B1 (en)
BR (1) BR112018005291A2 (en)
EA (1) EA037283B1 (en)
MA (2) MA42317B2 (en)
PH (1) PH12018500570A1 (en)
TN (1) TN2018000063A1 (en)
WO (1) WO2017048038A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520154B (en) * 2017-03-15 2023-08-04 株式会社Lg化学 Multivalent streptococcus pneumoniae vaccine compositions
KR102657910B1 (en) * 2017-07-18 2024-04-18 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 Immunogenic compositions with improved stability, enhanced immunogenicity and reduced reactogenicity and methods for their preparation
JOP20190242A1 (en) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920009729B1 (en) * 1990-08-29 1992-10-22 주식회사 녹십자 Mixed vaccine of d.p.t. and hepatitis b
KR920009729A (en) * 1990-11-26 1992-06-25 전금자 Pottery manufacturing method that generates far infrared rays
DE122010000016I1 (en) * 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Combined vaccines containing hepatitis B surface antigens and other antigens
EP2200582B1 (en) * 2007-09-12 2013-03-20 Galderma Research & Development Use of carriers as preservatives and pharmaceutical composition containing same
PE20100365A1 (en) * 2008-10-24 2010-05-21 Panacea Biotec Ltd NEW COMBINATION VACCINES WITH WHOLE CELL COUGH AND METHOD FOR THEIR PREPARATION
KR20140026392A (en) * 2011-03-02 2014-03-05 노파르티스 아게 Combination vaccines with lower doses of antigen and/or adjuvant

Also Published As

Publication number Publication date
EA037283B1 (en) 2021-03-04
MA52400B1 (en) 2023-01-31
BR112018005291A2 (en) 2018-10-09
TN2018000063A1 (en) 2019-07-08
EA201890502A1 (en) 2018-08-31
KR101864029B1 (en) 2018-06-01
WO2017048038A1 (en) 2017-03-23
KR20170033254A (en) 2017-03-24
PH12018500570A1 (en) 2018-09-17
MA52400A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
BR112018013387A2 (en) recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit
MA42317B2 (en) Combination vaccine composition for multiple administration
BR112018008102A2 (en) respiratory syncytial virus vaccine
CR20150454A (en) AMIDA COMPOUNDS FOR HIV TREATMENT
BR112018008078A2 (en) broad spectrum influenza virus vaccine
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
GB201101665D0 (en) Immunogenic compositions
CL2016003048A1 (en) Panonin analogues minimizes synthesis and use thereof.
MX349119B (en) Inactivated dengue virus vaccine.
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
BR112016026721A2 (en) virus-like vesicle-based vaccines (vlvs) to prevent or treat chronic hepatitis b (hbv) virus infection
BR112019003992A2 (en) neisseria meningitidis vaccine
PE20151588A1 (en) VACCINE AGAINST DENGUE VIRUS
CL2015001329A1 (en) Composition for immersion treatment of plant roots.
BR112017006085A2 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
BR112015021523A2 (en) composition of an acellular pertussis vaccine, and methods for vaccinating a subject against bordetella pertussis and for protecting a subject from pertussis
CO2021004556A2 (en) Composition of a combined vaccine comprising reduced doses of the inactivated polio virus and method of preparing the same
UA116697C2 (en) Composition for preventing and curing mycoplasma infection
CO2018013828A2 (en) Pharmaceutical compositions of morpholino phosphorodiamidate oligomer
MX2017006744A (en) Adjuvant compositions and related methods.
MX2017016858A (en) Immunogenic compositions.
BR112018007673A2 (en) epothilone analogs, synthesis methods, treatment methods and drug conjugates thereof.
AR117191A1 (en) IMMUNOGENIC COMPOSITIONS
BR112021002126A2 (en) Virus dispensing composition, and method for preparing a virus dispensing composition.
BR112018015247A2 (en) compound, process for preparing a compound, pharmaceutical composition